Skip to Content
Vaccines aren’t just for kids. Is your teen protected?

Ethionamide Disease Interactions

There are 4 disease interactions with ethionamide:

Major

Ethionamide (Includes Ethionamide) ↔ Hepatotoxicity

Severe Potential Hazard, High plausibility

Applies to: Diabetes Mellitus, Liver Disease, Alcoholism

The use of ethionamide is contraindicated in patients with severe liver damage. Like many other antituberculous agents, ethionamide is hepatotoxic. Transient elevations in bilirubin and serum SGOT (AST) and SGPT (ALT) have been reported in 5% of the patients treated with ethionamide. Hepatitis, with or without jaundice, has also been observed, particularly in patients with diabetes mellitus. Therapy with ethionamide should be administered cautiously in patients with liver disease, a history of alcoholism, or diabetes. Liver function tests should be measured at baseline and monthly during therapy, and ethionamide withdrawn at the first signs or symptoms suggestive of liver damage.

References

  1. Mandell GL, Bennett JE, Dolin R, eds.. "Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed." New York, NY: Churchill Livingston 1 (1995):
  2. "Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Major

Ethionamide (Includes Ethionamide) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

Ethionamide is primarily metabolized by the liver. Patients with liver disease may be at greater risk for adverse effects from ethionamide due to decreased drug clearance. Dosage reductions are recommended in these patients.

References

  1. "Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Major

Ethionamide (Includes Ethionamide) ↔ Peripheral Neuropathy

Severe Potential Hazard, Low plausibility

Applies to: Alcoholism, Malnourished, Peripheral Neuropathy, Diabetes Mellitus

Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent. Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism. Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.

References

  1. "Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Moderate

Ethionamide (Includes Ethionamide) ↔ Diabetes Mellitus

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

The use of ethionamide has occasionally been associated with poor diabetic control. Patients with diabetes mellitus should be monitored more closely during therapy with ethionamide, and their antidiabetic regimen adjusted accordingly.

References

  1. Mandell GL, Bennett JE, Dolin R, eds.. "Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed." New York, NY: Churchill Livingston 1 (1995):
  2. "Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.

ethionamide drug Interactions

There are 117 drug interactions with ethionamide

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide